Biopharma Partners

How Amprion Helps Accelerate Drug Development

Amprion helps biopharma partners address the following challenging questions related to drug development in neurodegenerative diseases:

Patient Stratification & Early Identification

• What underlying pathologies are in play?
• Do patient genetics affect responses to each candidate?
• Can patient genetics + PMCA effectively ID pre-clinical disease?
• How do pre-dosing responses predict target engagement post-dosing?
• Can PMCA inhibition pre-select patients most likely respond to each candidate?

Target Engagement

• Measures binding/sequestration of CSF prion-like proteins by immunoprecipitation
• How is binding affected by increasing concentrations of native protein?
• What concentrations are required for 80% & 95% target engagement?
• How do binding curves vary between different patients?
• Do antibody combinations outperform single species?
• How do monospecific versus bi-specific antibodies perform?

Direct Target Inhibition

• Which candidates & structures can directly inhibit prion amplification?
• How do IC50 levels correlate with CNS candidate concentrations?
• How do various candidates modulate aggregation kinetics?
• A single platform can evaluate antibodies, peptides, small molecules.

Disruption of Pre-formed Fibrils (Plaque/Tangle/Lewy Body)

• Which candidate concentrations are most effective?
• What is the disaggregation kinetics for each candidate?
• Is it possible to shift the equilibrium towards more inactive fibrils?
• Which candidates favor large fibrils versus smaller prion-like structures?
• Which degradative enzymes impact fibril structures?